Mei He, Ph.D.

Dr. Mei He, a researcher at the University of Kansas has just earned a five-year, $1.89 million National Institutes of Health grant to investigate how exosomes might be new avenue for understanding long-distance, non-contact cellular communications that control our immune systems.
Mei He, Ph.D.
He Laboratory

UF Cancer and Genetics Research Complex
Office: 0458 | Lab: 0475

T: (352) 273-9847
Department Affiliation: College of Pharmacy

Assistant Professor

Postdoc, Bioengineering

2008-2011 · University of California-Berkeley, USA,

Ph.D., Chemistry

2004-2008 · University of Alberta, Canada,

M.S., Pharmaceutical Chemistry

2000-2003 · Chongqing University, China,

B.S., Chemical Engineering, with Honors

1996-2000 · Chongqing University, China,

Dr. He has strong research expertise in extracellular vesicles and exosomes -mediated therapeutic delivery and biomarker discovery. She is named as the National Academy of Inventors Senior Member, the Board advisor of Gordon and Betty Moore Foundation and The Moore Inventor Fellowship review committee, and the Editorial Board Advisor for journal of Lab on Chip (LOC), also the Editorial Board member of Pharmaceutics and AAPS Taxonomy Committee. She received the NIH Maximizing Investigator’s Research Award for Early-Stage Investigators in 2019, and the LOC Emerging Investigator Award in 2019. The multiple publications from her research group on exosome-based cancer research received the Most Downloaded Articles of 2016 (LOC), the Featured Cover Story of 2018 (LOC), Technology Readers Choice Award of 2018 (SLAS), and Top 100 Read Articles of 2019 (Scientific Reports from Nature Publishing Group). Her recent publications on extracellular vesicles and exosomes have appeared in the journal of Nature Biomedical Engineering, the Journal of Extracellular Vesicles, and the Nature Communications Biology. Her research brings in novel microfluidic and nanotechnology for differentiating, isolating, and intravesicular loading exosomes precisely, which presents a new way for developing precision medicine. Her research innovation leads to more than 20 pending and issued patents, and she is also the founder of Clara Biotech Inc. and ExoDeL Inc.